Search

HARMONY: Better care of patients with hematologic malignancies kicked off!

“Combining data available from clinical trials as well as real world patients allows us to do more advanced analyses on possible treatment options that could be effective for individual patient or categories of patients”, said Jesús María Hernandez Rivas, Project…

Read more

EHA policy on double awarding

EHA is guided by the concept of supporting as many young investigators/clinicians as possible in their career development. Therefore, double awarding is not allowed.

Read more

EHA endorses the International COVID-19 Blood Cancer Coalition (ICBCC) Statement

On February 21, the COVID-19 Blood Cancer Coalition (ICBCC), a multi-stakeholder coalition including representatives from the global patient advocacy and clinical community, launched its Joint Patient Impact Statement and Recommendations for protecting immunocompromised blood cancer patients during the COVID-19 pandemic.

Read more

Starting this November: EHA Guidelines Workshops!

EHA has initiated a series of online workshops dedicated to guidelines (produced or endorsed by EHA) for diagnosis and treatment of hematologic diseases.

Read more

EHA-SAH Hematology Tutorial on Lymphoid Malignancies and Plasma Cell Dyscrasias

Dates: September 14-15, 2018
Location: Buenos Aires, Argentina
Chairs: D Fantl, R Foà
Co-chair: G Kusminsky

Following successful previous editions, EHA is organizing the second two-day tutorial in close collaboration with the Sociedad Argentina de Hematología (SAH) on “Lymphoid Malignancies and Plasma Cell Dyscrasias”.…

Read more

ABT-199: Novel Bcl-2 specific inhibitor updated results confirm substantial activity and durable responses in high-risk CLL.

Chronic Lymphocytic Leukaemia (CLL) is the most common leukemia in adults in the Western world and is diagnosed in approximately 5 persons per 100,000 population per year.

Read more